#United States #Atlanta #ViraxBiolabs #EmoryUniversity #ViraxImmune

Virax Biolabs Partners with Emory University for Clinical Studies

Virax Biolabs Group Limited, a biotechnology company publicly traded on NASDAQ with the ticker VRAX, is making significant strides in the field of immune response diagnostics. The firm recently announced a strategic partnership with Emory University's Center for the Advancement of Diagnostics for a Just Society, known as the ADJUST Center. This collaboration is set to advance clinical studies on ViraxImmune™, a proprietary testing technology that assesses immune profiles in patients, focusing initially on post-acute sequelae of SARS-CoV-2 (PASC), commonly referred to as long COVID.

Background

As the global community grapples with the long-term effects of COVID-19, millions of individuals are experiencing persistent symptoms attributed to long COVID and similar post-viral syndromes. These conditions often remain underdiagnosed, leaving many patients without effective diagnostic options. Virax Immune™ aims to bridge this gap by offering a more comprehensive assessment of immune health compared to conventional antibody tests, which primarily evaluate antibody presence rather than T-cell activity.

The Partnership Details

Under the Research Services Agreement (RSA) established between Virax and Emory University, the Emory Laboratory for Innovative Assay Development (ELIAD) will lead the patient recruitment process, execute testing, and analyze data. The clinical data generated from these studies will play a crucial role in supporting Virax's regulatory submissions and potential market introductions in the U.S.

The timing of this venture is particularly strategic, as Virax prepares for a pre-submission meeting with the U.S. Food and Drug Administration (FDA) scheduled for early September 2025. This meeting is intended to secure the FDA’s input regarding the regulatory pathway for ViraxImmune™ concerning its intended use in treating conditions like PASC. The feedback will help shape the pivotal U.S. clinical trial design and refine Virax's commercialization strategy.

Importance of the Collaboration

James Foster, the CEO of Virax Biolabs, highlighted the significance of partnering with Emory University, an institution renowned for its prowess in immunology and clinical research. He stated, "This partnership marks a critical step toward validating ViraxImmune™ in real-world patient populations. With the ongoing challenges posed by long COVID, ViraxImmune™ is strategically positioned to meet the pressing diagnostic needs of these patients."

Dr. Wilbur A. Lam, the Director of the ADJUST Center at Emory University, also expressed enthusiasm for the collaboration, noting the extensive gaps in understanding and diagnosing post-viral syndromes. He emphasized that immune profiling technologies like ViraxImmune™ could yield vital insights into patient immune functions, enabling more precise diagnoses and tailored treatment strategies.

Innovative Technology

ViraxImmune™ stands out for its focus on T-cell testing, specifically designed to assess the immune response profile of individual patients. Unlike standard antibody testing, which can miss crucial details of immune health, this innovative approach evaluates T-cell activity, thereby offering a more nuanced understanding of chronic and post-viral conditions.

Future Directions

Virax Biolabs remains firmly committed to leveraging its partnership with Emory University to drive advancements in immune response detection and diagnostics. As they prepare for their discussion with the FDA, the data obtained from the clinical studies will be pivotal in defining the future landscape of diagnostic options for long COVID and related syndromes.

This initiative is not just about immediate gains; it’s about establishing long-term value for shareholders and carving a niche for Virax as a leader in immune profiling diagnostics.

Conclusion

As the scientific community seeks effective ways to address the long-lasting impacts of viral infections such as COVID-19, collaborations like the one between Virax Biolabs and Emory University represent a beacon of hope. With continuous advancements and rigorous research, they aim to provide critical solutions that will help millions suffering from debilitating post-viral conditions regain their health and improve their quality of life. For more information about Virax Biolabs and its innovative products, visit www.viraxbiolabs.com.